ENDRA Life Sciences (NDRA) Other financing activities (2016 - 2025)

ENDRA Life Sciences has disclosed Other financing activities across 5 years of filings, most recently posting $2028.0 for Q4 2025.

• In Q4 2025, Other financing activities changed N/A year-over-year to $2028.0; the TTM figure through Dec 2025 stood at $262804.0 (changed N/A YoY), while the FY2025 annual figure was $35953.0, changed N/A from the prior year.
• Other financing activities declined to $2028.0 in Q4 2025, from $260776.0 in the prior quarter.
• Over the last five years, Other financing activities for NDRA reached as high as $260776.0 in Q1 2023 and fell as low as $2028.0 in Q4 2025.
• The 4-year median for Other financing activities is $26783.0 (2022), against an average of $106726.4.
• The widest YoY moves for Other financing activities: up 873.66% in 2023, down 873.66% in 2023.
• A 4-year view of Other financing activities shows it stood at $10052.0 in 2021, then surged by 2227.83% to $233993.0 in 2022, then grew by 11.45% to $260776.0 in 2023, then plunged by 99.22% to $2028.0 in 2025.
• According to Business Quant data, Other financing activities over the past three periods registered $2028.0, $260776.0, and $233993.0 for Q4 2025, Q1 2023, and Q2 2022 respectively.